Navigation Links
Ovarian cancer screening not catching early disease
Date:4/1/2009

BIRMINGHAM, Ala. The only available screening tests for ovarian cancer fail to catch early signs of the disease and often result in unnecessary surgery, said researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center.

The new study looked at a screening regimen that combines ultrasound and a blood test for CA-125, a marker for women's cancer.

Results showed the combo screening caught 70 percent of the ovarian cancers in their late stages, when effective treatment options are limited.

Knowing this screening limitation means the search has intensified for a better way to detect ovarian cancer, often called the "silent killer," said Edward Partridge, M.D., director of the UAB Comprehensive Cancer Center and the lead study author.

"We still have some comparison data to review, but right now it looks like the positive predictive value of these tests is pretty low," Partridge said.

The study puts the positive predictive value for both tests at around 1.6 percent per 100 positive screening results, a remarkably low positivity rate that led to many false positives, he said. False positives are erroneous signals of cancer where there is none.

The UAB results are published April 1 in the journal Obstetrics & Genecology.

One alarming trend noted in the study is how often transvaginal ultrasound led to a high rate of unnecessary removal of the ovaries, which means no cancer was detected in these organs post-surgery.

"This data suggests that we need a better screening tool. We need a test that is more sensitive and more specific so we find the cancer earlier and we catch the biological markers that give us stronger clues," Partridge said.

The study was part of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO trial) and included more than 72,000 women aged 55 to 74.

The PLCO results coincide with a British study published March 10 online in The Lancet Oncology that found combo screening for ovarian cancer was extremely successful in finding early stage cancers. But that still doesn't mean the screens led to a reduction in the ovarian cancer death rate, reported the British study authors from the University College London.

Ovarian cancer ranks as the fifth leading cause of female cancer death, and it is diagnosed primarily in women aged 55 and older. Early stages of the cancer cause somewhat vague symptoms and many malignancies go undetected until other organs and tissues are involved.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
2. Catching Ovarian Cancer Early May Miss Aggressive Tumors
3. Ovarian cancers detected early may be less aggressive, questioning effectiveness of screening
4. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
5. Combo Screening Doesnt Spot Early Ovarian Cancer
6. Early Detection Remains Key in Updated NCCN Guidelines for Ovarian Cancer
7. Combo of Tests Might Spot Ovarian Cancer Early
8. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
9. Fertility Drugs Do Not Increase Ovarian Cancer Risk
10. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
11. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
Breaking Medicine Technology: